van der Veen R C, Asghar S S, Uitdehaag B M, van der Helm H J, Hommes O R
Neuropharmacology. 1985 Nov;24(11):1139-42. doi: 10.1016/0028-3908(85)90206-0.
Suramin was tested for its ability to suppress experimental allergic encephalomyelitis. Prophylactic administration caused significant reduction in the severity of the disease, incidence of paralysis and cellular infiltration in nervous tissue. Therapeutic treatment with suramin also caused a reduction in the severity of the disease, the incidence of paralysis and cellular infiltration, but to a lesser extent. Significantly fewer animals were paralysed for more than two days on therapeutic treatment.
对苏拉明抑制实验性变态反应性脑脊髓炎的能力进行了测试。预防性给药使疾病严重程度、瘫痪发生率以及神经组织中的细胞浸润显著降低。用苏拉明进行治疗也使疾病严重程度、瘫痪发生率和细胞浸润有所降低，但程度较小。接受治疗的动物中，瘫痪超过两天的明显减少。
